MP 0250

Drug Profile

MP 0250

Alternative Names: MP0250

Latest Information Update: 25 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Molecular Partners AG
  • Class Antineoplastics; Proteins; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Hepatocyte growth factor inhibitors; Immunomodulators; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple myeloma
  • Phase I/II Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 18 Jun 2018 Updated safety and efficacy data from phase II trial in Multiple myeloma released by Molecular Partners
  • 01 Jun 2018 Updated efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 21 Apr 2018 Preliminary safety and efficacy data of phase II trial in Multiple myeloma released by the Molecular Partners
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top